Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Short

Showing results (171-180 of 346) with videos related to

Pageof 35
Sort By:
Leukemia & Lymphoma|November 28, 2024
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemiaNicholas J Short, Agnieszka Wierzbowska, Thomas Cluzeau, et al.
Leukemia|September 25, 2024
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphomaFarhad Ravandi, Jayastu Senapati, Nitin Jain, et al.
Acta Haematologica|June 19, 2022
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating MutationsSai Prasad Desikan, Farhad Ravandi, Naveen Pemmaraju, et al.
Leukemia|June 21, 2020
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemiaMansour Alfayez, Ghayas C Issa, Keyur P Patel, et al.
American Journal of Hematology|August 5, 2021
Development of TP53 mutations over the course of therapy for acute myeloid leukemiaYasmin Alwash, Joseph D Khoury, Mehrnoosh Tashakori, et al.
Cancer|December 7, 2018
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypesPrajwal C Boddu, Tapan M Kadia, Guillermo Garcia-Manero, et al.
Blood Cancer Journal|June 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemiaElias Jabbour, Caitlin R Rausch, Hannah Goulart, et al.
Leukemia|February 8, 2022
Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinibYuya Sasaki, Hagop M Kantarjian, Nicholas J Short, et al.
American Journal of Hematology|June 25, 2017
Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimensPreetesh Jain, Hagop Kantarjian, Nitin Jain, et al.
Blood Advances|August 5, 2025
Mini-Hyper-CVD plus Venetoclax and Navitoclax for Relapsed/Refractory Acute Lymphoblastic LeukemiaNicholas J Short, Hagop M Kantarjian, Nitin Jain, et al.
Pageof 35

Showing results (171-180 of 346) with videos related to

Sort By:
Pageof 35
Leukemia & Lymphoma|November 28, 2024
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemiaNicholas J Short, Agnieszka Wierzbowska, Thomas Cluzeau, et al.
Leukemia|September 25, 2024
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphomaFarhad Ravandi, Jayastu Senapati, Nitin Jain, et al.
Acta Haematologica|June 19, 2022
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating MutationsSai Prasad Desikan, Farhad Ravandi, Naveen Pemmaraju, et al.
Leukemia|June 21, 2020
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemiaMansour Alfayez, Ghayas C Issa, Keyur P Patel, et al.
American Journal of Hematology|August 5, 2021
Development of TP53 mutations over the course of therapy for acute myeloid leukemiaYasmin Alwash, Joseph D Khoury, Mehrnoosh Tashakori, et al.
Cancer|December 7, 2018
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypesPrajwal C Boddu, Tapan M Kadia, Guillermo Garcia-Manero, et al.
Blood Cancer Journal|June 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemiaElias Jabbour, Caitlin R Rausch, Hannah Goulart, et al.
Leukemia|February 8, 2022
Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinibYuya Sasaki, Hagop M Kantarjian, Nicholas J Short, et al.
American Journal of Hematology|June 25, 2017
Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimensPreetesh Jain, Hagop Kantarjian, Nitin Jain, et al.
Blood Advances|August 5, 2025
Mini-Hyper-CVD plus Venetoclax and Navitoclax for Relapsed/Refractory Acute Lymphoblastic LeukemiaNicholas J Short, Hagop M Kantarjian, Nitin Jain, et al.
Pageof 35